In 3 further patients with various levels of remission on different ABL1-inhibitors, only JAK2 V617Fpos colonies were identified adding up to 8/9 (89%) patients in which CFU-GM analyses hint towards a pre-existing JAK2 V617Fpos MPN. Here, JAK2 is linked to myeloproliferative disorder.